tetano
Editor, Senior Moderator
Expert Opin Biol Ther
. 2020 Aug 3;1-14.
doi: 10.1080/14712598.2020.1796963. Online ahead of print.
Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects
Khan Sharun[SUP] 1 [/SUP], Ruchi Tiwari[SUP] 2 [/SUP], Mohd Iqbal Yatoo[SUP] 3 [/SUP], Shailesh Kumar Patel[SUP] 4 [/SUP], Senthilkumar Natesan[SUP] 5 [/SUP], Jaideep Dhama[SUP] 6 [/SUP], Yashpal S Malik[SUP] 7 [/SUP], Harapan Harapan[SUP] 8 9 10 [/SUP], Raj Kumar Singh[SUP] 11 [/SUP], Kuldeep Dhama[SUP] 4 [/SUP]
Affiliations
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) has spread to several countries globally. Currently, there is no specific drug or vaccine available for managing COVID-19. Antibody-based immunotherapeutic strategies using convalescent plasma, monoclonal antibodies (mAbs), neutralizing antibodies (NAbs), and intravenous immunoglobulins have therapeutic potential.
Areas covered: This review provides the current status of the development of various antibody-based immunotherapeutics such as convalescent plasma, mAbs, NAbs, and intravenous immunoglobulins against COVID-19. The review also highlights their advantages, disadvantages, and clinical utility for the treatment of COVID-19 patients.
Expert opinion: In a pandemic situation such as COVID-19, the development of new drugs should focus on and expedite the strategies where safety and efficacy are proven. Antibody-based immunotherapeutic approaches such as convalescent plasma, intravenous immunoglobulins, and mAbs have a proven record of safety and efficacy and are in use for decades. Some of them are already being used to manage COVID-19 patients and found to be useful. However, the mAbs with virus neutralization potential is the need of the hour during this COVID-19 pandemic to be more specific and virus targeted. The research and investment need to be accelerated to bring them into clinical use for prophylactic and therapeutic purposes against COVID-19.
Keywords: COVID-19; SARS-CoV-2; convalescent plasma; coronavirus; immunoglobulin; immunotherapeutics; monoclonal antibodies; neutralizing antibodies.
. 2020 Aug 3;1-14.
doi: 10.1080/14712598.2020.1796963. Online ahead of print.
Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects
Khan Sharun[SUP] 1 [/SUP], Ruchi Tiwari[SUP] 2 [/SUP], Mohd Iqbal Yatoo[SUP] 3 [/SUP], Shailesh Kumar Patel[SUP] 4 [/SUP], Senthilkumar Natesan[SUP] 5 [/SUP], Jaideep Dhama[SUP] 6 [/SUP], Yashpal S Malik[SUP] 7 [/SUP], Harapan Harapan[SUP] 8 9 10 [/SUP], Raj Kumar Singh[SUP] 11 [/SUP], Kuldeep Dhama[SUP] 4 [/SUP]
Affiliations
- PMID: 32744917
- DOI: 10.1080/14712598.2020.1796963
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) has spread to several countries globally. Currently, there is no specific drug or vaccine available for managing COVID-19. Antibody-based immunotherapeutic strategies using convalescent plasma, monoclonal antibodies (mAbs), neutralizing antibodies (NAbs), and intravenous immunoglobulins have therapeutic potential.
Areas covered: This review provides the current status of the development of various antibody-based immunotherapeutics such as convalescent plasma, mAbs, NAbs, and intravenous immunoglobulins against COVID-19. The review also highlights their advantages, disadvantages, and clinical utility for the treatment of COVID-19 patients.
Expert opinion: In a pandemic situation such as COVID-19, the development of new drugs should focus on and expedite the strategies where safety and efficacy are proven. Antibody-based immunotherapeutic approaches such as convalescent plasma, intravenous immunoglobulins, and mAbs have a proven record of safety and efficacy and are in use for decades. Some of them are already being used to manage COVID-19 patients and found to be useful. However, the mAbs with virus neutralization potential is the need of the hour during this COVID-19 pandemic to be more specific and virus targeted. The research and investment need to be accelerated to bring them into clinical use for prophylactic and therapeutic purposes against COVID-19.
Keywords: COVID-19; SARS-CoV-2; convalescent plasma; coronavirus; immunoglobulin; immunotherapeutics; monoclonal antibodies; neutralizing antibodies.